STOCK TITAN

Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rhea-AI Summary

Syndax Pharmaceuticals announced its participation in the Cowen 2nd Annual Virtual Oncology Innovation Summit on May 20, 2021, at 12:00 p.m. ET. The management team will present details about their innovative cancer therapy pipeline, including SNDX-5613, axatilimab, and entinostat. A live webcast of the presentation can be accessed through the Company's website, with a replay available for a limited time thereafter.

Loading...
Loading translation...

Positive

  • Participation in a significant industry event enhances visibility.
  • Presentation of a promising pipeline of cancer therapies.

Negative

  • None.
Argus Session date unavailable
+1.06% session move Open Argus
Details

News Market Reaction – SNDX

The recorded move for SNDX in the trading session of this news was +1.06%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

WALTHAM, Mass., May 13, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Cowen 2nd Annual Virtual Oncology Innovation Summit on Thursday, May 20, 2021 at 12:00 p.m. ET.

A live webcast of the presentation can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. 

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com 
Tel 212.600.1902

Media Contact
Ted Held
ted.held@gcihealth.com
Tel 212.798.9842

SNDX-G

Cision View original content:http://www.prnewswire.com/news-releases/syndax-announces-participation-in-cowen-2nd-annual-virtual-oncology-innovation-summit-301290613.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Syndax participating in the Cowen 2nd Annual Virtual Oncology Innovation Summit?

Syndax will participate on May 20, 2021, at 12:00 p.m. ET.

What are the key therapies that Syndax Pharmaceuticals is developing?

Syndax is developing SNDX-5613, axatilimab, and entinostat.

How can I watch Syndax's presentation at the oncology summit?

The presentation can be accessed via a live webcast on Syndax's website.

What time does Syndax's presentation at the summit start?

The presentation starts at 12:00 p.m. ET.

Keep reading